Title |
Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia
|
---|---|
Published in |
Cochrane database of systematic reviews, July 2014
|
DOI | 10.1002/14651858.cd009268.pub2 |
Pubmed ID | |
Authors |
Magdolna Tardy, Maximilian Huhn, Werner Kissling, Rolf R Engel, Stefan Leucht |
Abstract |
Antipsychotic drugs are the core treatment for schizophrenia. Treatment guidelines state that there is no difference in efficacy between antipsychotic compounds, however, low-potency antipsychotic drugs are often clinically perceived as less efficacious than high-potency compounds, and they also seem to differ in their side-effects. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
France | 1 | 13% |
India | 1 | 13% |
United Kingdom | 1 | 13% |
Unknown | 5 | 63% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 75% |
Practitioners (doctors, other healthcare professionals) | 2 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 146 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 1% |
South Africa | 1 | <1% |
Unknown | 143 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 26 | 18% |
Student > Bachelor | 19 | 13% |
Researcher | 15 | 10% |
Student > Ph. D. Student | 13 | 9% |
Student > Doctoral Student | 8 | 5% |
Other | 23 | 16% |
Unknown | 42 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 40 | 27% |
Psychology | 18 | 12% |
Nursing and Health Professions | 12 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 8 | 5% |
Agricultural and Biological Sciences | 5 | 3% |
Other | 16 | 11% |
Unknown | 47 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 June 2023.
All research outputs
#1,554,782
of 25,728,855 outputs
Outputs from Cochrane database of systematic reviews
#3,302
of 13,136 outputs
Outputs of similar age
#14,968
of 241,332 outputs
Outputs of similar age from Cochrane database of systematic reviews
#61
of 231 outputs
Altmetric has tracked 25,728,855 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,136 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,332 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 231 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.